QbD Group
    On Demand Webinar

    Pharmacovigilance and Risk Management in Innovative Therapies

    The webinar discusses the evolving pharmacovigilance and risk management environment of innovative therapies, emphasizing safety challenges in cell, CAR T, and RNA-based treatments, as well as gaps in regulation and surveillance strategies. Participants will gain insight into the origin and impact of safety concerns in these therapies, alongside ongoing developments in RNA-based treatments.

    On Demand
    60 min
    Pharmacovigilance · Pharma & Biotech
    English

    About the webinar

    As innovative therapies like cell, CAR T, and RNA-based treatments transform modern medicine, they also present new and complex safety challenges.

    This webinar delves into the critical aspects of pharmacovigilance and risk management necessary to support these advances. Participants will gain insight into the origin and impact of safety concerns in cell and CAR T therapies.

    Pharmacovigilance has become an essential discipline to ensure the safety of patients receiving innovative therapies. We will also discuss how authorities are addressing these treatments to minimize the risks.

    The session will also cover the ongoing revolution in RNA-based therapies, outlining their therapeutic potential alongside emerging safety risks. Attendees will learn about current pharmacovigilance strategies tailored to these novel products and explore future perspectives in managing evolving risks.

    Designed for professionals in drug safety, regulatory affairs, and clinical development, this webinar offers a vital opportunity to stay informed and prepared in an ever-changing therapeutic landscape.

    Register now

    What you'll learn

    • Discover strategic approaches to risk management in the development of innovative treatments.
    • Understanding on the unique safety challenges associated with cell and CAR T therapies.
    • Learn the fundamentals and mechanisms behind RNA-based therapeutic technologies.
    • Identify key pharmacovigilance concerns specific to RNA-based therapies and how to address them.
    • Prepare for the future of drug safety by recognizing evolving risks and opportunities in cutting-edge therapies.

    Learn from the best

    Speakers

    Join us as our expert speakers share valuable insights and practical knowledge drawn from extensive industry experience.

    Dr. Almudena Del Castillo Saiz

    Dr. Almudena Del Castillo Saiz

    Head of Drug Safety & Vigilance, QbD Group

    Dr. Almudena del Castillo, a Medical Doctor and Specialist in Family and Community Medicine, is an expert in pharmacovigilance within the pharmaceutical industry. With a strong interest in regulatory affairs and drug safety, she has held roles at major pharmaceutical companies like Pfizer. She later applied her combined scientific and business vision at leading life sciences consultancies, including Pharmalex and PLG, as VP of Sales and Business Development. Currently, as Global Division Head of Drug Safety and Vigilance at QbD Group, she drives globally focused solutions in safety, regulatory compliance, and strategic medical affairs.
    Anam Ahmad

    Anam Ahmad

    Senior PV Associate

    Anam holds a BSc in Pharmaceutical and Cosmetic Sciences and has developed a strong career in pharmacovigilance, supporting clinical trials, marketing authorisation applications, and post-marketing activities in the UK and internationally. She acts as the UK QPPV and local pharmacovigilance contact, ensuring regulatory compliance and effective safety oversight. She brings broad expertise in pharmacovigilance and is recognized for her proactive, solutions-focused approach and strong commitment to medicine safety.
    Dr. Laura Fragata Tavares

    Dr. Laura Fragata Tavares

    Pharmacovigilance Consultant

    Dr. Laura Fragata holds a Doctor of Veterinary Medicine degree and is trained as a Qualification and Validation Coordinator. She began her career in quality assurance within the biopharmaceutical industry, working on medical device projects and ensuring compliance with industry standards. Currently, Laura works in the pharmacovigilance department at our HQ in Belgium, where she supports various safety-related activities across different types of health products in both clinical and post-marketing settings.

    Register here

    Keep watching

    More webinars

    AI in Life Sciences: Session 2, Your Questions Answered On Demand Webinar

    AI in Life Sciences: Session 2, Your Questions Answered

    Software Solutions & ServicesMar 31, 2026

    Adopting AI in life sciences holds enormous potential, but navigating GxP requirements adds real complexity. In this joint session, QbD Group and delaware walk you through how to deploy AI that is trustworthy, validated, and inspection-ready, covering data governance, explainability, and lifecycle management. Building on the first session, this edition dedicates more time to answering your questions, addressing the topics raised by the audience in Session 1, and opening the floor for live debate and discussion.

    Watch now

    Strengthen Your Pharmacovigilance System

    QbD Group offers a full range of pharmacovigilance services to ensure your products meet compliance standards while safeguarding patient safety.

    Pharmacovigilance services

    We use cookies to enhance your experience

    We use essential cookies for site functionality and optional analytics cookies to improve our services. Read our Privacy Policy and Cookie Policy.